Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥8,730 JPY
Change Today +330.00 / 3.93%
Volume 577.6K
As of 1:00 AM 11/26/15 All times are local (Market data is delayed by at least 15 minutes).

kaken pharmaceutical co ltd (4521) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/18/15 - ¥12,720
52 Week Low
01/7/15 - ¥4,442
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KAKEN PHARMACEUTICAL CO LTD (4521)

Related News

No related news articles were found.

kaken pharmaceutical co ltd (4521) Related Businessweek News

No Related Businessweek News Found

kaken pharmaceutical co ltd (4521) Details

Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. It operates through two segments, Pharmaceuticals and Real Estate. The company offers pharmaceutical and medical devices products, such as Artz, an anti-osteoarthritis drug to treat knee joint pain accompanied by rheumatoid arthritis; Clenafin, a triazole compound for topical medication for onychomycosis; Seprafilm, an anti-adhesive absorbent barrier; Lipidil, an anti-hyperlipidemia product; and Fiblast Spray, a wound-healing drug. Its pharmaceutical and medical devices products also include Procylin, which is used to treat chronic artery occlusive diseases and pulmonary hypertension; Adofeed, a pain- and inflammation-relieving plaster; Mentax, a topical product used to treat superficial mycosis; Ebrantil, a a1 blocker to treat dysuria and hypertension; Berasus to treat pulmonary arterial hypertension; and Clexane, an anticoagulant for the treatment of patients who undergo podiatric or abdominal surgery. In addition, the company provides agrochemicals, including Polyoxins that is used as fungicide; and Pentoxazone, a rice herbicide. Further, it offers animal health products comprising Salinomycin, an anti-coccidial feed additive for chicken; and Colistin sulfate, a polypeptide antibiotic effective against gram-negative bacteria. Additionally, the company is developing KCB-1D for the treatment of periodontitis; KAG-308, a Phase II clinical product to treat Ulcerative colitis; BBI-4000 that is in pre-clinical stage to treat primary focal hyperhidrosis; and SI-657, which is in Phase-III clinical trials to treat Enthesopathy. It primarily focuses on fields, such as inflammation, allergies, and pain relief, as well as fungal infection. The company also rents Bunkyo Green Court commercial facility. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

1,503 Employees
Last Reported Date: 06/26/15
Founded in 1917

kaken pharmaceutical co ltd (4521) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kaken pharmaceutical co ltd (4521) Key Developments

Kaken Pharmaceutical Co. Ltd. Declares Second Quarter Dividend, Payable on November 30, 2015; Provides Dividend Guidance for the Full Year of 2015

Kaken Pharmaceutical Co. Ltd. declared second quarter dividend of JPY 34.00 per share compared to JPY 27.00 per share a year ago. Payable on November 30, 2015 For the full year of fiscal 2015, the company expects to pay dividend of JPY 78 against JPY 32 a year ago.

Kaken Pharmaceutical Co. Ltd. Announces Consolidated and Non-Consolidated Earnings Results for the Six Months Ended September 30, 2015; Provides Consolidated and Non-Consolidated Earnings Guidance for the Year Ending March 31, 2016

Kaken Pharmaceutical Co. Ltd. announced consolidated and non-consolidated earnings results for the six months ended September 30, 2015. On consolidated basis, net sales were JPY 54,973 million against JPY 44,232 million a year ago. Operating income was JPY 18,443 million against JPY 8,806 million a year ago. Ordinary income was JPY 18,573 million against JPY 8,677 million a year ago. Net income attributable to owners of the company was JPY 12,483 million against JPY 5,639 million a year ago. Net income per basic share was JPY 301.39 against JPY 134.56 a year ago. Net cash provided by operating activities was JPY 10,551 million against JPY 3,175 million a year ago. Income before income taxes was JPY 18,523 million against JPY 8,654 million a year ago. Purchase of property, plant and equipment was JPY 1,616 million against JPY 749 million a year ago. Purchase of intangible assets was JPY 33 million against JPY 47 million a year ago. On non-consolidated basis, net sales were JPY 53,851 million against JPY 43,349 million a year ago. Operating income was JPY 18,119 million against JPY 8,496 million a year ago. Ordinary income was JPY 18,277 million against JPY 8,411 million a year ago. Net income was JPY 12,295 million against JPY 5,481 million a year ago. The company provided consolidated earnings guidance for the year ending March 31, 2016. For the year, the company expects net sales of JPY 107,900 million, operating income of JPY 32,200 million, ordinary income of JPY 32,400 million, net income attributable to owners of the company of JPY 19,200 million and net income per basic share of JPY 463.66. The company provided non-consolidated earnings guidance for the fiscal year 2015. For the year, the company expects net sales of JPY 105,700 million, operating income of JPY 31,500 million, ordinary income of JPY 31,800 million and net income of JPY 16,900 million.

Kaken Pharmaceutical Co. Ltd., Q2 2016 Earnings Call, Nov 10, 2015

Kaken Pharmaceutical Co. Ltd., Q2 2016 Earnings Call, Nov 10, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4521:JP ¥8,730.00 JPY +330.00

4521 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4521.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4521 Industry Range
Price/Earnings 18.6x
Price/Sales 3.4x
Price/Book 4.1x
Price/Cash Flow 18.3x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KAKEN PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at